Key Developments: DaVita HealthCare Partners Inc (DVA)
126.82USD
19 Jun 2013
$-2.68 (-2.07%)
$129.50
$129.21
$129.40
$126.79
611,861
768,518
$131.33
$91.68
Latest Key Developments (Source: Significant Developments)
DaVita HealthCare Partners Inc's DaVita Labs And Myriad Genetics Inc's Myriad RBM Announce Biomarker Research Collaboration
DaVita Labs, a unit of DaVita HealthCare Partners Inc. and Myriad RBM, a wholly-owned subsidiary of Myriad Genetics Inc announced a research collaboration to conduct protein biomarker discovery research with the goal of developing and commercializing diagnostic tests that could benefit in the treatment of dialysis patients. DaVita and Myriad have identified potential opportunities where diagnostic tests utilizing blood-based protein biomarkers could improve the quality of life for patients and potentially lower overall healthcare costs. The primary area of focus will include the prediction of vascular access failure. Specimens from the DaVita biorepository will be processed on the Myriad RBM DiscoveryMAP platform for the quantification of more than 300 important proteins. DiscoveryMAP analyzes protein biomarkers correlated with inflammatory, metabolic and renal disease conditions that could have meaningful utility as diagnostic criteria for dialysis patients. Myriad is expected to begin processing specimens associated with this collaboration in fiscal year 2014. Full Article
Berkshire Hathaway Inc May Boost DaVita HealthCare Partners Inc Stake To 25%-Reuters
Reuters reported that Berkshire Hathaway Inc, the investor in DaVita HealthCare Partners Inc, has entered an agreement allowing it to nearly double its stake in the U.S. operator of dialysis clinics to 25%. According to a regulatory filing, the companies on Tuesday entered a standstill agreement, which is often used to prevent unsolicited takeovers, indicating the maximum percentage of shares that Berkshire can own. Berkshire owned about 15 million DaVita shares, or 14.2%, as of March 4, according to another regulatory filing. Full Article
DaVita HealthCare Partners Inc Raises Low End Of Prior FY 2013 EBIT Guidance To A Range In Line With Analysts' Estimates
DaVita HealthCare Partners Inc updated it fiscal 2013 guidance and expects consolidated operating income (EBIT) to be in the range of $1.800 billion to $1.900 billion. The previous consolidated EBIT was expected to be in the range of $1.750 billion to $1.900 billion. According to I/B/E/S Estimates, analysts are expecting the Company to report EBIT of $1.846 billion for fiscal 2013. Full Article
Hagens Berman Sobol Shapiro LLP Files Two Lawsuits In Federal Court In Colorado Alleging That Davita Healthcare Partnersinc's Actions Led To Deaths Of Two Dialysis Patients
Hagens Berman Sobol Shapiro LLP, a law firm with experience prosecuting cases against healthcare providers and the pharmaceutical industry, announced that it has filed two lawsuits in Federal Court in Colorado alleging that DaVita Healthcare PartnersInc's actions led to the deaths of two dialysis patients. The lawsuits further allege that the problems that caused those deaths have impacted thousands of dialysis patients across the country, and seek class action status. The suits claim that DaVita failed to recognize that part of the treatment it used in dialysis was causing dangerously high levels of bicarbonates in the patients, which the suit claims caused the deaths of the two patients cited in the suits, and potentially many other unreported deaths and injuries, including cardiac arrest and stroke. Hagens Berman has also filed suits against Fresenius Medical Care North America (FMC) (Fresenius), the company who manufactured and distributed the two products. According to those lawsuits, an internal memo dated Nov. 4, 2011, reveals that Fresenius knew of the dangers associated with GranuFlo and NaturaLyte, two dialysis products, far in advance of informing the FDA. Moreover, the complaints allege that Fresenius made adjustments at its own clinics to reduce the impact on patients, showing it was aware of the problem. Full Article
DaVita HealthCare Partners Inc Reaffirms FY 2013 EBIT Guidance
DaVita HealthCare Partners Inc announced that for fiscal 2013, it still expects consolidated operating income to be in the range of $1.750 billion to $1.900 billion including the operating results of HCP. According to I/B/E/S Estimates, analysts are expecting the Company to report EBIT of $1.831 billion for fiscal 2013. Full Article
BioScrip Inc Closes Acquisition of DaVita HealthCare Partners Inc's Subsidiary HomeChoice Partners Inc
BioScrip Inc announced the February 1, 2013 closing of its previously announced agreement to acquire HomeChoice Partners Inc, provider of alternate-site infusion pharmacy services, for $70.0 million in cash. HomeChoice was a majority-owned subsidiary of DaVita HealthCare Partners Inc. Full Article
DaVita HealthCare Partners Inc's DaVita Closes Deal to Provide Dialysis Services in Taiwan
DaVita, the kidney care division of DaVita HealthCare Partners Inc and a provider of kidney care services, announced the formation of a joint venture with Riches Healthcare (RHC), through which a new entity – DaVita Taiwan – will provide services to four dialysis clinics. DaVita will own a majority share of the joint venture entity. The four clinics currently serviced by RHC are located in and around Taipei, have a combined number of 88 stations and are providing hemodialysis treatments to more than 250 patients. Full Article
DaVita HealthCare Partners Inc's DaVita Inc Acquires Dialysis Centers In Portugal And Poland
DaVita HealthCare Partners Inc's DaVita Inc announced that it has acquired nine dialysis centers from Fresenius Medical Care (FMC), provider of dialysis services and manufacturer of dialysis products. Five of the clinics are located in Portugal and four clinics are located in Poland. Financial terms of the transaction were not disclosed. Full Article
BioScrip Inc Enters Into Agreement To Acquire DaVita HealthCare Partners Inc's HomeChoice Partners, Inc.
BioScrip Inc announced that it has entered into a definitive agreement to acquire HomeChoice Partners, Inc. ("HomeChoice"), a provider of alternate-site infusion pharmacy services, for $70.0 million in cash. HomeChoice is a majority-owned subsidiary of DaVita HealthCare Partners Inc. The purchase price is subject to adjustment pursuant to the terms of the agreement including potential additional consideration based on the results of operations. BioScrip also expects to realize the value of a future tax benefit estimated at $3.9 million as a result of the transaction. The transaction is subject to customary closing conditions, including regulatory approval. The company expects the transaction will close in the first quarter of 2013. Full Article
DaVita Inc And HealthCare Partners Finalize Merger
DaVita Inc announced the closing of its previously announced merger with HealthCare Partners, the operators of medical groups and physician networks. The merged entity is now named DaVita HealthCare Partners Inc. HealthCare Partners will be an operating division of DaVita HealthCare Partners. The HealthCare Partners senior management team will continue to manage the existing business, and Dr. Margolis has joined the board of directors and become Co-Chairman of DaVita HealthCare Partners alongside Co-Chairman Mr. Thiry. Dr. Margolis will also be a member of the Clinical Performance Committee of the Board. Full Article
Berkshire may boost DaVita stake to 25 percent
- Warren Buffett's Berkshire Hathaway Inc , the largest investor in DaVita HealthCare Partners Inc , has entered an agreement allowing it to nearly double its stake in the largest U.S. operator of dialysis clinics to 25 percent.
Earnings vs. 
Estimates
Thomson Reuters is the world's largest international multimedia news agency, providing investing news, world news, business news, technology news, headline news, small business news, news alerts, personal finance, stock market, and mutual funds information available on Reuters.com, video, mobile, and interactive television platforms. Thomson Reuters journalists are subject to an Editorial Handbook which requires fair presentation and disclosure of relevant interests.
NYSE and AMEX quotes delayed by at least 20 minutes. Nasdaq delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
